A Methodology Study of Brain Imaging of Pain-Killers in Post-Traumatic Neuropathic Pain Patients
Information source: Pfizer
Information obtained from ClinicalTrials.gov on November 03, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Placebo (Drug); Pregabalin (Drug); Tramadol SR (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Overall contact: Pfizer CT.gov Call Center, Phone: 1-800-718-1021
Summary
This study is a methodology study designed to discover whether a brain imaging technology is
a better way of compare the relative sensitivities of fMRI and subjective psychometric
assessments of pain to multiple doses of pregabalin and tramadol SR in a cross-over clinical
study design.
Clinical Details
Official title: A Methodology Study to Assess the Feasibility of Using Functional Magnetic Resonance Imaging (fMRI) to Quantify the Effects of Analgesic Drugs in Post-Traumatic Neuropathic Pain Subjects
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Crossover Assignment, Pharmacodynamics Study
Primary outcome: Voxel-wise BOLD and ASL brain activation signals across the whole brain and in defined brain regions in response to painful (brush allodynia and heat) stimuli, ongoing pain and visual (checkerboard) stimuli
Secondary outcome: Psychological assessment scoresNeuropathic Pain Symptom Inventory score Doleur neuropathic 4 "DN4" results Present Pain Intensity score Daily Pain Score
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of post-traumatic peripheral NeP syndrome, including post-surgical NeP.
- Presence of dynamic mechanical allodynia (brush allodynia) in the dermatomes
associated with specific dermatomes.
- Brush allodynia score of ≥4 and calculated average pain score of ≥4 on an 11-point
numerical rating scale by the completion of down-titration of existing medications.
right-handed
Exclusion Criteria:
- Subjects with trigeminal neuralgia, central pain (due to cerebrovascular lesions,
multiple sclerosis and/or traumatic spinal cord injuries including spinal surgery).
- Complex region pain syndromes, phantom limb pain, radiculopathy, painful diabetic
neuropathy or post- Herpetic neuralgia.
- Subjects with any other co-existing pain which he/she or a qualified pain physician
cannot differentiate from NeP of peripheral origin.
- Subjects with diabetes mellitus and with an HbA1C value of >10% upon measurement at
screening.
Locations and Contacts
Pfizer CT.gov Call Center, Phone: 1-800-718-1021
Pfizer Investigational Site, Portsmouth, Hampshire PO3 6AD, United Kingdom; Recruiting
Pfizer Investigational Site, Solihull, West Midlands B91 2JL, United Kingdom; Not yet recruiting
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: September 2008
Ending date: July 2009
Last updated: October 13, 2008
|